Applied BioCode Aktsia

Applied BioCode P/B

P/B (hinna ja raamatupidamisliku väärtuse suhe) ettevõttest Applied BioCode (6598.TW) seisuga 8. aug 2026 on 3,84. Eelmisel aastal oli P/B (hinna ja raamatupidamisliku väärtuse suhe) 2,81 — muutus 36,63% (kõrgem).

P/B

3,84

YoY

36,63%

Viimati uuendatud:

P/B (hinna ja raamatupidamisliku väärtuse suhe) ettevõttest Applied BioCode on 2026 3,84 . P/B (hinna ja raamatupidamisliku väärtuse suhe) ettevõttest Applied BioCode oli 2025 2,81 . See väheneb 36,63% kõrgem võrreldes eelmise aastaga.
Access this data via the Eulerpool API

Applied BioCode Aktsiate analüüs

Mida Applied BioCode teeb? Applied BioCode Corp is a California-based company that focuses on the development and marketing of diagnostic instruments and tests. The company was founded in 2004 by an experienced management team and has since developed a number of groundbreaking technologies to improve the diagnosis of diseases such as cancer, infectious diseases, and autoimmune diseases. The business model of Applied BioCode Corp is based on the development of innovative diagnostic instruments and test systems based on proprietary technologies. The company has a strong partnership with a leading manufacturer of diagnostic automation systems, allowing a wide range of tests for various diseases to be offered. Applied BioCode Corp also works closely with leading research and development organizations to leverage the latest insights in the field of diagnostics. One of the divisions of Applied BioCode is molecular diagnostics, which is an essential component of modern medicine. Molecular diagnostics enables the detection of genetic changes and deviations related to diseases. Applied BioCode's technology allows for rapid and precise identification of pathogens in clinical samples such as blood, urine, and tissue samples. Another important area for Applied BioCode is infectious disease diagnostics. The company has developed a range of test systems based on a variety of infectious diseases such as influenza, tuberculosis, and sexually transmitted diseases such as chlamydia and gonorrhea. These tests can be performed individually or as a group to facilitate disease diagnosis and improve treatment. Applied BioCode also offers tests for the detection of oncological markers. These tests are crucial for the early detection of cancer and monitoring the treatment of cancer patients. Applied BioCode's technology enables rapid and precise identification of cancer cells in blood or tissue, which can improve the effectiveness of treatment. Another important product of Applied BioCode is the BioCode Analyzer, an automated diagnostic instrument. The BioCode Analyzer is a high-throughput system capable of performing multiple tests simultaneously. The analyzer is equipped with a disposable chip that allows for quick and easy diagnosis. This makes the BioCode Analyzer a powerful tool for laboratory automation, providing fast and accurate diagnosis for a variety of diseases. Applied BioCode is also dedicated to researching and developing new technologies. The company has an active pipeline of new products and technologies to further improve diagnostic accuracy and the number of feasible tests. Applied BioCode is also developing new applications for its technologies to improve the diagnosis and treatment of diseases in various ways. In summary, Applied BioCode Corp plays an important role in the field of diagnostic technology. The company has developed a wide range of innovative diagnostic tests and instruments that enable diseases to be quickly and accurately detected. With its strong partnership with leading diagnostic automation system manufacturers and research organizations, Applied BioCode will continue to stay at the forefront and improve diagnostic practice. Applied BioCode on üks populaarsemaid ettevõtteid Eulpoolist.

Sageli esitatud küsimused Applied BioCode aktsia kohta

Applied BioCode P/B (hinna ja raamatupidamisliku väärtuse suhe) on 2026. aastal 3,84.

P/B (hinna ja raamatupidamisliku väärtuse suhe) ettevõttest Applied BioCode muutus 2,81 -st 3,84 -ks, mis vastab 36,63% muutusele. Väärtus on kõrgem kui eelmisel aastal.

Eulpoolist leiate P/B (hinna ja raamatupidamisliku väärtuse suhe) Applied BioCode täieliku ajaloolise arengu alates 2006. aastast – koos aastate väärtustega, graafikutega ja üksikasjalike analüüsidega.

Hinna ja raamatupidamisliku väärtuse suhe võrdleb ettevõtte turuhinda tema raamatupidamislikuga. Madal P/B võib näidata alakursiga aktsiat, samas kõrge P/B võib viidata ülehinnanguele või tugevatele kasvuootustele.

P/B = aktsiakurs / raamatupidamislik väärtus aktsia kohta

P/B (hinna ja raamatupidamisliku väärtuse suhe) hindamiseks on oluline võrrelda seda sama tööstuse ja sektori ettevõtetega. Eulpoolis leiate P/B (hinna ja raamatupidamisliku väärtuse suhe) jaoks otsesed tööstusesisesed võrdlused.

Hea väärtus varieerub tööstuse ja ettevõtte arenguetapi järgi. Eulpoolis saate P/B (hinna ja raamatupidamisliku väärtuse suhe) Applied BioCode võrrelda sektori konkurentidega ja tööstuse keskmisega, et hinnata selle atraktiivsust.

Access this data via the Eulerpool API

Hindamine — Applied BioCode

Kõik finantsnäitajad — Applied BioCode